Form 4: Spyre Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Heidy King-Jones, See Remarks of Spyre Therapeutics, Inc., sold 28,933 shares of common stock on October 1, 2026.
Summary
- Option exercise/conversion: acquired 28,933 Common Stock at $14.50 ($419,528) on October 1, 2026; holds 31,778 after (Direct).
- Open-market sale: disposed of 400 Common Stock at $89.24 ($35,696) on October 1, 2026; holds 31,378 after (Direct).
- Open-market sale: disposed of 16,605 Common Stock at $90.35 ($1,500,262) on October 1, 2026; holds 14,773 after (Direct).
- Open-market sale: disposed of 7,228 Common Stock at $91.35 ($660,278) on October 1, 2026; holds 7,545 after (Direct).
- Open-market sale: disposed of 2,100 Common Stock at $92.70 ($194,670) on October 1, 2026; holds 5,445 after (Direct).
- Open-market sale: disposed of 2,600 Common Stock at $93.46 ($242,996) on October 1, 2026; holds 2,845 after (Direct).
- Option exercise/conversion: disposed of 28,933 Stock Option (Right to Buy) on October 1, 2026; holds 482,478 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $2,633,902 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Heidy King-Jones — Officer (See Remarks)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-01 | Option exercise/conversion | Common Stock | 28,933 | $15 | $419.5K | 31,778 |
| 2026-10-01 | Open-market sale | Common Stock | 400 | $89 | $35.7K | 31,378 |
| 2026-10-01 | Open-market sale | Common Stock | 16,605 | $90 | $1.5M | 14,773 |
| 2026-10-01 | Open-market sale | Common Stock | 7,228 | $91 | $660.3K | 7,545 |
| 2026-10-01 | Open-market sale | Common Stock | 2,100 | $93 | $194.7K | 5,445 |
| 2026-10-01 | Open-market sale | Common Stock | 2,600 | $93 | $243.0K | 2,845 |
| 2026-10-01 | Option exercise/conversion | Stock Option (Right to Buy) | 28,933 | — | — | 482,478 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-01 | Option exercise/conversion (28,933 shares) |
| 2026-10-01 | Open-market sale (400 shares) |
| 2026-10-01 | Open-market sale (16,605 shares) |
| 2026-10-01 | Open-market sale (7,228 shares) |
| 2026-10-01 | Open-market sale (2,100 shares) |
| 2026-10-01 | Open-market sale (2,600 shares) |
| 2026-10-01 | Option exercise/conversion (28,933 shares) |
Keywords
insider transaction, Form 4, SYRE, Spyre Therapeutics, Inc., bearish, Heidy King-Jones
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.